Video summary

132: The Hidden Power of Ketones: Fueling + Signaling with Dr. Ben Bikman

Main summary

Key takeaways

Science and Nature

Scientific concepts, discoveries, and nature/biological phenomena

Ketones as signaling molecules (not just fuel)

  • Beta-hydroxybutyrate (BHB) is described as a hormone-like metabolite that can both:
    • Provide energy (e.g., via ATP generation)
    • Act as a cell signal, including:
      • Receptor binding
      • Anti-inflammatory actions
      • Epigenetic regulation of gene expression

Overall theme: ketones coordinate metabolic state with immune and gene-regulatory responses.

Ketone bodies and stereochemistry

  • The three classical ketone bodies:
    • BHB
    • Acetoacetate
    • Acetone
  • BHB abundance
    • BHB is the most abundant circulating ketone body (~70%).
  • Mirror-image forms
    • D-BHB: more prevalent
    • L-BHB: reported as a smaller fraction, sometimes ~10% of circulating ketones
  • Video claims about stereochemistry:
    • Both forms can be used as energy
    • Both can act as signaling molecules, with DBHB emphasized as having somewhat higher affinity for a receptor at lower concentrations
    • (Later sections also claim stereoselectivity is not strict for certain pathways, such as NLRP3)

Physiological ketone ranges

  • Fed/typical conditions: often very low BHB, often below detection (commonly < 0.1 mM)
  • Overnight fast: ~0.3 mM
  • Prolonged fasting / ketogenic diet: can reach > 1 mM (sometimes 1–4 mM)
  • Extreme cases (diabetic ketoacidosis): typically high teens/20s (mostly not typical outside type 1 diabetes)
  • The ~1–2 mM range is highlighted as where many BHB signaling effects become relevant.

BHB production and fuel metabolism

  • Where BHB is made
    • BHB is synthesized primarily in liver mitochondria during high rates of fatty acid oxidation.
  • How BHB is used as fuel (described pathway)
    • Entry via MCT1/MCT2 transporters
    • Conversion back to acetoacetate by BDH1
    • Formation of acetoacetyl-CoA
    • Cleavage to products entering the citrate cycle → ATP production
  • Liver vs other tissues
    • The liver produces ketones but is described as not utilizing them, lacking necessary catabolic enzymes
    • Ketones are exported to other tissues
  • Tissues that use ketones
    • Many mitochondrial-containing tissues (e.g., brain, heart, skeletal muscle)

Hormone-like signaling via specific receptors

GPR109A / HR2 (“niacin receptor”)

  • Role
    • BHB is described as an endogenous ligand.
  • Proposed signaling cascade
    • BHB binds GPR109A (a Gi/o-coupled receptor)
    • Inhibits adenylyl cyclase
    • Lowers cAMP
    • Reduces activity of protein kinase A
  • Immune and CNS relevance
    • Expressed on immune cells including macrophages, neutrophils, and microglia
    • Also described in retinal pigment epithelial cells and microglia
  • Key experimental findings described
    • Retina: mice lacking GPR109A show more inflammatory cell infiltration; BHB reduces recruitment only when GPR109A is functional
    • Stroke models: a Nature Communications paper is said to show ketogenic diet protection depends on GPR109A; receptor knockout removes infarct-size reduction
    • Mechanistic phenotype shift: immune cells shift toward a neuroprotective phenotype, producing factors such as prostaglandin D2
  • Stereoselectivity claim
    • Not strictly stereo-selective; both D and L can activate
    • DBHB appears effective at somewhat lower levels

FFAR3 / GPR41 (free fatty acid receptor 3)

  • Initial characterization
    • FFAR3 is introduced as a sensor for short-chain fatty acids from gut bacteria/fermented foods (e.g., acetate, propionate, butyrate).
  • Video claim: BHB as an agonist
    • In sympathetic neurons, BHB is said to inhibit N-type calcium channels
    • Predicted outcome: reduced sympathetic outflow
    • Proposed fasting effect: reduced norepinephrine release / dampened sympathetic tone
  • Cancer-related findings described
    • In non-small cell lung cancer models:
      • BHB is said to suppress proliferation, migration, and invasion
    • Removing the receptor abolishes BHB’s anti-tumor effects, supporting receptor-mediated signaling rather than fuel competition alone

Direct anti-inflammatory mechanism: inhibition of the NLRP3 inflammosome

  • NLRP3 inflammosome (function)
    • An innate immune danger-sensing complex that detects signals such as:
      • ATP
      • Uric acid crystals
      • Bacterial toxins
    • Activates caspase-1
    • Caspase-1 processes pro-inflammatory cytokines:
      • IL-1β
      • IL-18
  • Disease links attributed to IL-1β dysregulation
    • Type 2 diabetes, atherosclerosis, gout, Alzheimer’s, multiple sclerosis, and other inflammatory/autoimmune syndromes

2015 Nature Medicine “landmark” paper (as described)

  • Core claim
    • BHB specifically inhibits NLRP3 (not NLRC4 or AIM2)
  • Mechanistic details
    • Prevents potassium efflux (early step in NLRP3 activation)
    • Reduces:
      • ASC oligomerization
      • ASC speck formation
  • Receptor independence claim
    • Effects persist in GPR109A knockout models
    • Not dependent on:
      • AMPK
      • Autophagy
      • ROS reduction
      • BHB oxidation via the citrate cycle
    • Described as direct action by the BHB molecule
  • Stereoselectivity claim
    • Not stereo-selective: both DBHB and LBHB inhibit NLRP3
    • Suggested implication: racemic ketone supplements may preserve anti-inflammatory effects

Disease-model examples described

  • Gout
    • BHB attenuates inflammation triggered by uric acid crystals via NLRP3
  • Alzheimer’s disease models
    • BHB reduces:
      • Amyloid plaque formation
      • Microgliosis
      • Inflammatory signaling associated with NLRP3 inhibition
  • Clinical correlation claim
    • Alzheimer’s patients reportedly show lower BHB levels in blood and brain than age-matched controls (proposed link: reduced anti-inflammatory signaling)

Epigenetic gene regulation via histone deacetylase (HDAC) inhibition

  • BHB as an HDAC inhibitor
    • Described as an endogenous inhibitor of Class I histone deacetylases, specifically:
      • HDAC1
      • HDAC2
      • HDAC3
  • Mechanistic background
    • DNA is wrapped around proteins (histones)
    • Histone acetylation loosens chromatin → increases transcription accessibility
    • HDACs remove acetyl groups → generally suppress gene expression
  • Reported findings (as described)
    • Inhibition of HDAC activity by BHB at concentrations as low as ~1 mM
    • Increased acetylation at promoters of antioxidant/protective genes including:
      • FOXO3A
      • MT2 (metallothionein 2)
    • Mouse protection against oxidative stress is described as mediated by HDAC inhibition and upregulated antioxidant defenses

Post-translational modification: beta-hydroxybutyrylation

  • The video describes beta hydroxybutyrylation:
    • BHB can be covalently attached to lysine residues on histones and other proteins
    • Presented as a metabolic-to-gene expression coupling mechanism
    • Key distinction: it changes proteins directly, not only via inhibition of epigenetic “erasers”

Integrated “mitochondria-health and resilience” framework

  • The video ties signaling outcomes to mitochondrial function:
    • BHB metabolism produces reducing equivalents (NADH, FADH2) that feed electron transport → ATP
    • A debated idea: ketone metabolism may be more thermodynamically efficient than glucose
  • Oxidative stress mitigation
    • Via HDAC inhibition and antioxidant gene upregulation
  • Inflammation–mitochondria feedback loop
    • Inflammation → mitochondrial damage is described as a vicious cycle
    • NLRP3 inhibition reduces inflammatory cytokines (e.g., IL-1β) → protects mitochondria
  • Immune cell phenotype modulation
    • Via GPR109A to support tissue cleanup rather than perpetuating inflammation
  • Emphasis
    • These effects are portrayed as simultaneous during fasting, ketogenic diets, and exogenous ketone use

Therapeutic direction: exogenous ketone supplements

  • How they’re described
    • Exogenous BHB (e.g., BHB salts or BHB acid, described as “go BHB”) can elevate blood BHB without strict carb restriction
  • Clinical trials described
    • Exploring anti-inflammatory/neuroprotective effects in conditions such as:
      • Alzheimer’s disease
      • Heart failure (positioned as “superfuel” / adaptive ketone use)
      • Autoimmune conditions, especially where NLRP3 activation contributes to progression

Researchers/sources featured (named in the subtitles)

  • Dr. Ben Bickman (presenter; described as a metabolic scientist and professor of cell biology)
  • Eric Verdin (Gladstone Institutes group)
  • Nature Communications paper (stroke/neuroprotection dependence on GPR109A; authors not named in subtitles)
  • Nature Medicine (2015) paper (BHB inhibition of the NLRP3 inflammosome; authors not named in subtitles)
  • Ben Bickman’s lab (self-referenced as having published a report on gout/NLRP3; specific paper not named in subtitles)

Original video